Logo image of MRNA

MODERNA INC (MRNA) Stock Fundamental Analysis

NASDAQ:MRNA - Nasdaq - US60770K1079 - Common Stock - Currency: USD

34.74  +1.01 (+2.99%)

Fundamental Rating

3

Taking everything into account, MRNA scores 3 out of 10 in our fundamental rating. MRNA was compared to 571 industry peers in the Biotechnology industry. While MRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. MRNA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MRNA has reported negative net income.
MRNA had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MRNA reported negative net income in multiple years.
In multiple years MRNA reported negative operating cash flow during the last 5 years.
MRNA Yearly Net Income VS EBIT VS OCF VS FCFMRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

MRNA's Return On Assets of -25.18% is fine compared to the rest of the industry. MRNA outperforms 73.36% of its industry peers.
MRNA has a better Return On Equity (-32.67%) than 76.91% of its industry peers.
Industry RankSector Rank
ROA -25.18%
ROE -32.67%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
MRNA Yearly ROA, ROE, ROICMRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

Looking at the Gross Margin, with a value of 62.73%, MRNA belongs to the top of the industry, outperforming 80.28% of the companies in the same industry.
In the last couple of years the Gross Margin of MRNA has declined.
MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.91%
GM growth 5YN/A
MRNA Yearly Profit, Operating, Gross MarginsMRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRNA has more shares outstanding
Compared to 5 years ago, MRNA has more shares outstanding
MRNA has a better debt/assets ratio than last year.
MRNA Yearly Shares OutstandingMRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
MRNA Yearly Total Debt VS Total AssetsMRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

MRNA has an Altman-Z score of 3.27. This indicates that MRNA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.27, MRNA is in the better half of the industry, outperforming 75.67% of the companies in the same industry.
MRNA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, MRNA is in line with its industry, outperforming 45.47% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.27
ROIC/WACCN/A
WACC9.52%
MRNA Yearly LT Debt VS Equity VS FCFMRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

MRNA has a Current Ratio of 3.67. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.67, MRNA is in line with its industry, outperforming 42.98% of the companies in the same industry.
MRNA has a Quick Ratio of 3.62. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
MRNA has a Quick ratio of 3.62. This is comparable to the rest of the industry: MRNA outperforms 44.41% of its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.62
MRNA Yearly Current Assets VS Current LiabilitesMRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

6

3. Growth

3.1 Past

MRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.53%, which is quite impressive.
The Revenue for MRNA has decreased by -52.75% in the past year. This is quite bad
Measured over the past years, MRNA shows a very strong growth in Revenue. The Revenue has been growing by 122.01% on average per year.
EPS 1Y (TTM)28.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-554.55%
Revenue 1Y (TTM)-52.75%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-65.64%

3.2 Future

MRNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.37% yearly.
Based on estimates for the next years, MRNA will show a very strong growth in Revenue. The Revenue will grow by 22.61% on average per year.
EPS Next Y-11.76%
EPS Next 2Y6.85%
EPS Next 3Y10.93%
EPS Next 5Y18.37%
Revenue Next Year-25.1%
Revenue Next 2Y-4.65%
Revenue Next 3Y5.02%
Revenue Next 5Y22.61%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MRNA Yearly Revenue VS EstimatesMRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
MRNA Yearly EPS VS EstimatesMRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRNA. In the last year negative earnings were reported.
Also next year MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRNA Price Earnings VS Forward Price EarningsMRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRNA Per share dataMRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.85%
EPS Next 3Y10.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

NASDAQ:MRNA (2/21/2025, 2:56:10 PM)

34.74

+1.01 (+2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-14 2025-02-14/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners72.76%
Inst Owner Change6.45%
Ins Owners5.46%
Ins Owner Change0.04%
Market Cap13.37B
Analysts65
Price Target63.88 (83.88%)
Short Float %11.66%
Short Ratio3.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)55.12%
Min EPS beat(2)8.71%
Max EPS beat(2)101.54%
EPS beat(4)4
Avg EPS beat(4)32.45%
Min EPS beat(4)3.51%
Max EPS beat(4)101.54%
EPS beat(8)7
Avg EPS beat(8)2.9%
EPS beat(12)9
Avg EPS beat(12)4.05%
EPS beat(16)12
Avg EPS beat(16)4.18%
Revenue beat(2)2
Avg Revenue beat(2)23.24%
Min Revenue beat(2)0.45%
Max Revenue beat(2)46.04%
Revenue beat(4)4
Avg Revenue beat(4)48.29%
Min Revenue beat(4)0.45%
Max Revenue beat(4)78.74%
Revenue beat(8)8
Avg Revenue beat(8)36.49%
Revenue beat(12)10
Avg Revenue beat(12)27.34%
Revenue beat(16)12
Avg Revenue beat(16)19.08%
PT rev (1m)-5.9%
PT rev (3m)-28.48%
EPS NQ rev (1m)3.82%
EPS NQ rev (3m)-14.32%
EPS NY rev (1m)2.03%
EPS NY rev (3m)3.36%
Revenue NQ rev (1m)-11.77%
Revenue NQ rev (3m)-21.37%
Revenue NY rev (1m)-2%
Revenue NY rev (3m)-1.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.13
P/FCF N/A
P/OCF N/A
P/B 1.23
P/tB 1.23
EV/EBITDA N/A
EPS(TTM)-8.87
EYN/A
EPS(NY)-9.91
Fwd EYN/A
FCF(TTM)-10.54
FCFYN/A
OCF(TTM)-7.81
OCFYN/A
SpS8.41
BVpS28.33
TBVpS28.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.18%
ROE -32.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.73%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.91%
GM growth 5YN/A
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 556.09%
Cap/Sales 32.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.67
Quick Ratio 3.62
Altman-Z 3.27
F-Score5
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-554.55%
EPS Next Y-11.76%
EPS Next 2Y6.85%
EPS Next 3Y10.93%
EPS Next 5Y18.37%
Revenue 1Y (TTM)-52.75%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-65.64%
Revenue Next Year-25.1%
Revenue Next 2Y-4.65%
Revenue Next 3Y5.02%
Revenue Next 5Y22.61%
EBIT growth 1Y6.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.98%
EBIT Next 3Y20.6%
EBIT Next 5Y19.47%
FCF growth 1Y-6.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.66%
OCF growth 3YN/A
OCF growth 5YN/A